Sharps Technology, Inc. has exciting news as it announces the commencement of shipments for its innovative product lines, SecureGard™ and SoloGard™ smart safety syringes. Based in Hungary, Sharps Technology has invested significantly in modernizing its manufacturing capabilities to ensure high-quality, efficient production.
As the company transitions into a commercial-stage, revenue-generating entity, these initial shipments mark a pivotal milestone. The shipments cater to three customer orders and include the first commercial order of SoloGard under a substantial $50 million supply agreement with a prominent U.S.-based leader in IV flushing solutions. This particular delivery consists of customized 10mL SoloGard smart safety syringes, designed with features such as ultra-low waste design, standard luer lock compatibility, and re-use prevention technology. This inaugural order amounts to $400,000 and signifies the beginning of a five-year contract aiming to supply up to 500 million syringes.
Sharps Technology’s commitment to innovation has been evident through its dedication to advanced molding and automation technologies, which have been instrumental in meeting the anticipated increase in demand under this supply agreement during the latter half of 2025.
In addition to the SoloGard shipment, Sharps also delivered SecureGard smart safety syringes to a Hungarian vaccine provider, fulfilling a $100,000 purchase order. The SecureGard technology features an integrated active recessed safety system, underscoring Sharps’ dedication to safety and efficiency. This order represents the customer’s first commercial purchase, highlighting the growing global demand for secure and effective syringe technologies.
Further diversifying its market presence, Sharps initiated shipment of 200,000 units of 1mL low dead space syringes to a Swiss provider of cosmetic, dental, and ophthalmic injectable therapies. These syringes will be utilized for a specialized injection pen for delivering Botox, marking the first tranche of a million-unit order. This shipment showcases Sharps’ versatility in operating across different therapeutic markets and meeting specific technical needs for high-end injectable delivery systems.
Sharps Technology’s Chief Executive Officer, Robert Hayes, emphasized this milestone in the company’s journey, stating, “For the first time, we are recognizing product revenue across multiple product lines and global markets.” This transition illustrates the culmination of years’ worth of research and development, strategic planning, and significant manufacturing investments. With upgraded facility capabilities in Hungary, Sharps is well-positioned to scale quickly to meet both immediate and long-term contractual demands.
All production activities occur in Sharps’ enhanced Hungarian facility, which has undergone substantial improvements to support high-volume, high-precision production. The company continues to build its inventory while expanding its capacity to support current and future contracts under long-term strategic agreements.
The innovations offered by Sharps, particularly in its smart safety syringe product lines, stem from a commitment to reducing waste and increasing safety, integrating both passive and active safety features. Specialized copolymer technology is also leveraged to cater to the prefillable syringe market segment, positioning Sharps as a leader in the industry.
Looking ahead, the management team at Sharps Technology is optimistic about strengthening relationships with its partners and driving substantial growth in the upcoming quarters. The successful execution of strategic plans and manufacturing investments reflects the company’s capacity to innovate and adapt in a rapidly evolving healthcare landscape.
In conclusion, Sharps Technology’s commitment to delivering advanced healthcare solutions is evident as it embarks on this promising phase of operational milestone achievements. The recent shipments underline the company’s dedication to not only enhancing patient safety but also addressing the growing needs of the healthcare market worldwide. As we monitor their progress, it’s clear that Sharps Technology is setting the stage to become a crucial player in the medical device sector with a strong emphasis on sustainability and safety.
Source link
